← Back to Search

Monoclonal Antibodies

GR-MD-02 for Non-alcoholic Fatty Liver Disease (NASH-FX Trial)

Phase 2
Waitlist Available
Research Sponsored by Galectin Therapeutics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 weeks

Summary

A Randomized, Controlled, Double-blind, Parallel Group, Single Center Phase 2 Clinical Trial to Evaluate Multiple Non-Invasive Liver Fibrosis Imaging Methods in the Assessment of the Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis in Patients with NASH with Advanced Fibrosis

Eligible Conditions
  • Non-alcoholic Fatty Liver Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 16 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Mean Change in Liver Fibrosis of Corrected T1 (cT1) Mapping (LiverMultiScan -LMS)
Secondary study objectives
Baseline-adjusted Change in Liver Stiffness With MR-elastography (MRE)
Baseline-adjusted Change in Liver Stiffness by FibroScan®

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: GR-MD-02Active Control1 Intervention
Active
Group II: PlaceboPlacebo Group1 Intervention
Placebo

Find a Location

Who is running the clinical trial?

Galectin Therapeutics Inc.Lead Sponsor
11 Previous Clinical Trials
697 Total Patients Enrolled
2 Trials studying Non-alcoholic Fatty Liver Disease
388 Patients Enrolled for Non-alcoholic Fatty Liver Disease
~3 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top